The trajectory of copyright's flagship drug presents a nuanced case for stakeholders in the drug sector. While initially a phenomenal success, producing billions, the patent lapse and the subsequent entry of cheaper versions have drastically affected earnings. This poses questions about the long-term sustainability of related drug developments a… Read More